This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Manning, R. G. Articles by Wolfangel, R. G. Search for Related Content Social Bookmarking                         What's this?

Pharmacy Involvement With Positron-Emitting Radiopharmaceuticals

Vanderbilt University Hospital, Nashville, TN 37232-2675

Robert G. Wolfangel

Vanderbilt University Hospital, Nashville, TN 37232-2675

Positron emission tomography (PET) is an imaging process that relies on positron-emitting nuclides with very short physical half-lives (ranging from seconds to minutes). Exceptional resolution in PET imaging enables studies of the CNS (eg, highlighting deviant cell metabolism), and cardiovascular system (eg, identifying areas of reduced blood flow before coronary artery bypass surgery), among others. Increasing in popularity, PET radiopharmaceuticals pose a unique challenge to the nuclear pharmacist relative to product synthesis and quality control testing. Establishment of process validation programs with emphasis on quality, purity, and safety is all important. Various elements of process validation and quality control testing are discussed as they pertain to PET radiopharmaceuticals and the professional role of the nuclear pharmacist.

Journal of Pharmacy Practice, Vol. 2, No. 3, 185-190 (1989)
DOI: 10.1177/089719008900200308


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?